64 related articles for article (PubMed ID: 17291625)
1. Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
Kanat O; Evrensel T; Kurt E; Keskin K; Akcali U; Manavoglu O
Lung Cancer; 2007 Apr; 56(1):143-4. PubMed ID: 17291625
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.
Tsunoda T; Koizumi T; Hayasaka M; Hirai K; Koyama S; Takabayashi Y; Fujimoto K; Kubo K
Cancer Chemother Pharmacol; 2004 Aug; 54(2):173-7. PubMed ID: 15127230
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).
Biesma B; Manegold C; Smit HJ; Willems L; Legrand C; Passioukov A; van Meerbeeck JP; Giaccone G;
Eur J Cancer; 2006 Jul; 42(10):1399-406. PubMed ID: 16759850
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
[TBL] [Abstract][Full Text] [Related]
9. Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer.
Hsiao SC; Su WC
Natl Med J India; 2009; 22(2):67-9. PubMed ID: 19852339
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of outcomes of Taxol + Cisplatin and Taxol + Nedaplatin chemotherapy regimens for advanced non-small cell lung cancer].
Cai YP; Xu S; Lin SJ
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):74-5. PubMed ID: 20211076
[No Abstract] [Full Text] [Related]
11. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
Kocak M; Mayadagli A; Ozkan A; Parlak C; Demir O; Marti A; Dogan Eren M; Kaya S; Gumus M
J BUON; 2007; 12(4):471-6. PubMed ID: 18067204
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Yoh K; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y
Anticancer Res; 2012 Sep; 32(9):4131-5. PubMed ID: 22993373
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
Nakamura M; Koizumi T; Hayasaka M; Yasuo M; Tsushima K; Kubo K; Gomi K; Shikama N
Cancer Chemother Pharmacol; 2009 May; 63(6):1091-6. PubMed ID: 18818921
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
Cho SH; Go SI; Lee GW; Kang JH; Kim HG; Kim SH; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS
Lung Cancer; 2010 Jul; 69(1):94-8. PubMed ID: 19796840
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
17. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
18. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.
D'Amato G; Rocha Lima C; Mahany JJ; Muro-Cacho C; Haura EB
Lung Cancer; 2004 Jun; 44(3):381-90. PubMed ID: 15140552
[TBL] [Abstract][Full Text] [Related]
19. Study shows 2-year survival advantage for docetaxel.
Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
[No Abstract] [Full Text] [Related]
20. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study.
Seto T; Takezako Y; Nakamura H; Takeda K; Inoue F; Semba H; Eguchi K
Int J Clin Oncol; 2004 Oct; 9(5):378-82. PubMed ID: 15549588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
